Trial · NCT05579249
A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America
NCT05579249, Phase 4, Completed, Novo Nordisk A/S; results first posted 2026-01-14
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America. Trials, record NCT05579249. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05579249
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America
- NCT number
- NCT05579249
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 500 participants, actual
- Lead sponsor
- Novo Nordisk A/S
- Conditions
- Obesity
- Interventions
- Semaglutide, Orlistat, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide
- First posted
- 2022-10-13
- Last updated
- 2026-01-14
- Results first posted
- 2026-01-14
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants Who Achieved Greater Than or Equal to (≥) 10.0 Percent (%) Body Weight Reduction (Yes/no) | At end of treatment (week 52) | Number of participants who achieved greater than or equal to 10.0% body weight reduction (yes/no) at week 52 is presented. |
| Secondary | Percentage Change in Body Weight | Baseline (week 0), end of treatment (week 52) | Percentage change in body weight from week 0 to week 52 is presented. |
| Secondary | Change in Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT) Physical Function Domain | Baseline (week 0), end of treatment (week 52) | The IWQOL-Lite-CT is a 20-item, obesity-specific patient-reported outcome (PRO) instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity-related health-related quality of life (HRQoL): physical (7 items), and psychosocial (13 items). A 5-item subset of the physical domain, the physical-function composite is also supported. Items in the physical-function composite describe physical impacts related to general and specific physical activities. All items in the physical domain are rated on either a 5-point frequency ("never" to "always") scale or a 5-point truth ("not at all true" to "completely true") scale. Total score of IWQOL-Lite-CT composite ranges from 0 to 100, with higher scores reflecting better quality of life. This outcome measure shows results for physical function domain. |
| Secondary | Number of Participants Who Achieved Greater Than or Equal to (≥) 15.0% Body Weight Reduction (Yes/no) | At end of treatment (week 52) | Number of participants who achieved more than or equal to 15.0% body weight reduction (yes/no) at week 52 is presented. |
| Secondary | Number of Participants Who Achieved Greater Than or Equal to (≥) 20.0% Body Weight Reduction (Yes/no) | At end of treatment (week 52) | Number of participants who achieved more than or equal to 20.0% body weight reduction (yes/no) at week 52 is presented. |
| Secondary | Number of Participants Who Achieved Change in Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT) Physical Function Domain Score Greater Than or Equal to (≥) 14.6 (Yes/no) | At end of treatment (week 52) | The IWQOL-Lite-CT is a 20-item, obesity-specific patient-reported outcome (PRO) instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity-related health-related quality of life (HRQoL): physical (7 items), and psychosocial (13 items). A 5-item subset of the physical domain, the physical-function composite is also supported. Items in the physical-function composite describe physical impacts related to general and specific physical activities. All items in the physical domain are rated on either a 5-point frequency ("never" to "always") scale or a 5-point truth ("not at all true" to "completely true") scale. Total score of IWQOL-Lite-CT composite ranges from 0 to 100, with higher scores reflecting better quality of life. This outcome measure shows results for physical function domain score ≥ 14.6. |
| Secondary | Percentage of Days Covered (PDC) by Study Product | From week 0 to week 52 | Percentage of days covered by study product from week 0 to week 52 is presented. The percentage of days covered by the study product is determined by the duration on the study product divided by the planned study duration, multiplied by 100. |
| Secondary | Number of Participants Covered by Study Product Greater Than or Equal to (≥) 80% of Days (Yes/no) | At end of treatment (week 52) | Number of participants covered by study product ≥80% of days (yes/no) from week 0 to week 52 is presented. |
| Secondary | Change in Work Limitations Questionnaire 25-item Version (WLQ-25), Total Score (TS) | Baseline (week 0), end of treatment (week 52) | Work Limitations Questionnaire (WLQ-25) is a 25-item questionnaire that measures how health problems affect job performance and productivity over the past two weeks, using a 5-point Likert scale. It covers four domains: Time Management (5 items), Physical Demands (6), Mental/Interpersonal (9), and Output Demands (5). Each item is scored from 1 to 5, with subscale scores calculated as the average item score, then converted to a 0-100 scale using the formula: WLQ Scale Score= 25 × (average item score - 1). Thus, each subscale ranges from 0 (no limitation) to 100 (maximum limitation). The WLQ total score is computed by applying specific weights to each subscale and summing them: 0.00048 × Time scale + 0.00036 × Physical scale + 0.00096 × Mental/Interpersonal scale + 0.00106 × Output scale. This total is then transformed into the proportion of productivity loss using the formula: (1 - exp(-total score)). |
Source ClinicalTrials.gov
Outcomes9
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants Who Achieved Greater Than or Equal to (≥) 10.0 Percent (%) Body Weight Reduction (Yes/no) | At end of treatment (week 52) | Full analysis set included all randomized participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Percentage Change in Body Weight | Baseline (week 0), end of treatment (week 52) | Full analysis set included all randomized participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Percentange change in body weight | MEAN |
| SECONDARY | Change in Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT) Physical Function Domain | Baseline (week 0), end of treatment (week 52) | Full analysis set included all randomized participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Score on a scale | MEAN |
| SECONDARY | Number of Participants Who Achieved Greater Than or Equal to (≥) 15.0% Body Weight Reduction (Yes/no) | At end of treatment (week 52) | Full analysis set included all randomized participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants Who Achieved Greater Than or Equal to (≥) 20.0% Body Weight Reduction (Yes/no) | At end of treatment (week 52) | Full analysis set included all randomized participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants Who Achieved Change in Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT) Physical Function Domain Score Greater Than or Equal to (≥) 14.6 (Yes/no) | At end of treatment (week 52) | Full analysis set included all randomized participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Percentage of Days Covered (PDC) by Study Product | From week 0 to week 52 | Full analysis set included all randomized participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Percentage of days covered | MEAN |
| SECONDARY | Number of Participants Covered by Study Product Greater Than or Equal to (≥) 80% of Days (Yes/no) | At end of treatment (week 52) | Full analysis set included all randomized participants. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Change in Work Limitations Questionnaire 25-item Version (WLQ-25), Total Score (TS) | Baseline (week 0), end of treatment (week 52) | Full analysis set included all randomized participants Overall number of participants analyzed = participants with available data for this outcome measure. | Score on a scale | MEAN |
Source ClinicalTrials.gov
Results by group28
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Who Achieved Greater Than or Equal to (≥) 10.0 Percent (%) Body Weight Reduction (Yes/no) | Semaglutide 2.4 mg | Yes | 132 | Participants | |
| Number of Participants Who Achieved Greater Than or Equal to (≥) 10.0 Percent (%) Body Weight Reduction (Yes/no) | Other Anti-obesity Medications (AOMs) | Yes | 61 | Participants | |
| Number of Participants Who Achieved Greater Than or Equal to (≥) 10.0 Percent (%) Body Weight Reduction (Yes/no) | Semaglutide 2.4 mg | No | 75 | Participants | |
| Number of Participants Who Achieved Greater Than or Equal to (≥) 10.0 Percent (%) Body Weight Reduction (Yes/no) | Other Anti-obesity Medications (AOMs) | No | 116 | Participants | |
| Percentage Change in Body Weight | Semaglutide 2.4 mg | -13.6 | Standard Deviation 8.7 | Percentange change in body weight | |
| Percentage Change in Body Weight | Other Anti-obesity Medications (AOMs) | -7.4 | Standard Deviation 7.3 | Percentange change in body weight | |
| Change in Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT) Physical Function Domain | Semaglutide 2.4 mg | 25.6 | Standard Deviation 21.2 | Score on a scale | |
| Change in Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT) Physical Function Domain | Other Anti-obesity Medications (AOMs) | 22.6 | Standard Deviation 24.4 | Score on a scale | |
| Number of Participants Who Achieved Greater Than or Equal to (≥) 15.0% Body Weight Reduction (Yes/no) | Semaglutide 2.4 mg | Yes | 93 | Participants | |
| Number of Participants Who Achieved Greater Than or Equal to (≥) 15.0% Body Weight Reduction (Yes/no) | Other Anti-obesity Medications (AOMs) | Yes | 25 | Participants |
1 to 10 of 28Source ClinicalTrials.gov
See all 28 results by groupParticipant flow10
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Semaglutide 2.4 mg | 250 | |
| Overall Study | STARTED | Other Anti-obesity Medications (AOMs) | 250 | |
| Overall Study | Full Analysis Set | Semaglutide 2.4 mg | 250 | |
| Overall Study | Full Analysis Set | Other Anti-obesity Medications (AOMs) | 250 | |
| Overall Study | Safety Analysis Set | Semaglutide 2.4 mg | 242 | |
| Overall Study | Safety Analysis Set | Other Anti-obesity Medications (AOMs) | 242 | |
| Overall Study | COMPLETED | Semaglutide 2.4 mg | 214 | |
| Overall Study | COMPLETED | Other Anti-obesity Medications (AOMs) | 191 | |
| Overall Study | NOT COMPLETED | Semaglutide 2.4 mg | 36 | |
| Overall Study | NOT COMPLETED | Other Anti-obesity Medications (AOMs) | 59 |
Source ClinicalTrials.gov
Adverse events18
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Amyotrophic lateral sclerosis | Nervous system disorders | Semaglutide 2.4 mg | 1 | 242 | 1 |
| serious | Amyotrophic lateral sclerosis | Nervous system disorders | Other Anti-obesity Medications (AOMs) | 0 | 242 | 0 |
| serious | Atrioventricular block complete | Cardiac disorders | Semaglutide 2.4 mg | 1 | 242 | 1 |
| serious | Atrioventricular block complete | Cardiac disorders | Other Anti-obesity Medications (AOMs) | 0 | 242 | 0 |
| serious | Cholecystitis | Hepatobiliary disorders | Semaglutide 2.4 mg | 0 | 242 | 0 |
| serious | Cholecystitis | Hepatobiliary disorders | Other Anti-obesity Medications (AOMs) | 2 | 242 | 2 |
| serious | Drug hypersensitivity | Immune system disorders | Semaglutide 2.4 mg | 0 | 242 | 0 |
| serious | Drug hypersensitivity | Immune system disorders | Other Anti-obesity Medications (AOMs) | 1 | 242 | 1 |
| serious | Abortion spontaneous | Pregnancy, puerperium and perinatal conditions | Semaglutide 2.4 mg | 1 | 242 | 1 |
| serious | Abortion spontaneous | Pregnancy, puerperium and perinatal conditions | Other Anti-obesity Medications (AOMs) | 2 | 242 | 2 |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Semaglutide 2.4 mg | 0 | 250 |
| Total, all-cause mortality | Other Anti-obesity Medications (AOMs) | 2 | 250 |
| Total, other adverse events | Semaglutide 2.4 mg | 0 | 242 |
| Total, other adverse events | Other Anti-obesity Medications (AOMs) | 0 | 242 |
| Total, serious adverse events | Semaglutide 2.4 mg | 3 | 242 |
| Total, serious adverse events | Other Anti-obesity Medications (AOMs) | 8 | 242 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Semaglutide 2.4 mg vs Other Anti-obesity Medications (AOMs): deaths from any cause | Trial comparisons |
| Semaglutide 2.4 mg vs Other Anti-obesity Medications (AOMs): serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05579249
GET https://conductscience.org/api/trials/v1/NCT05579249/results?page=2